MedTrace Logo

Brief Cognitive Behavioral Therapy for Military Populations

NCT02038075 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2023-12-12

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to compare the effectiveness of brief cognitive-behavioral therapy (B-CBT) for the treatment of suicidality, including suicidal ideation and attempts (regardless of Axis I or II diagnosis) among active duty military personnel. The standard null hypothesis will involve tests conducted comparing improvement following B-CBT (treatment duration of 12 weeks) to treatment as usual (TAU). The primary outcome comparisons will include both direct markers of suicidality (i.e. suicide, suicide attempts) and indirect markers including associated symptomatology (i.e. suicidal ideation, intent, anxiety, depression, hopelessness, substance abuse, and sleep disturbance), along with remission of psychiatric diagnoses. Secondary purposes include the prospective investigation of suicide risk factors and warning signs to explore these variables' ability to predict subsequent suicidal behavior following an index attempt.

Conditions

Interventions

BEHAVIORAL

Brief Cognitive Behavioral Therapy (BCBT)

BEHAVIORAL

Treatment As Usual (TAU)

Sponsors & Collaborators

  • University of Memphis

    collaborator OTHER

  • The University of Texas Health Science Center at San Antonio

    collaborator OTHER

  • University of Utah

    lead OTHER

Principal Investigators

  • Michael D Rudd, PhD, ABPP · National Center for Veterans Studies & The University of Utah

  • Craig J Bryan, PsyD, ABPP · National Center for Veterans Studies & The University of Utah

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02038075 on ClinicalTrials.gov